Trial Profile
A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naive HIV-1 Infected Subjects With Selected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Transmitted Resistance Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms DRIVE BEYOND
- Sponsors Merck Sharp & Dohme
- 03 Nov 2020 Status changed from active, no longer recruiting to completed.
- 16 Aug 2019 Results published in the JAIDS
- 31 Oct 2018 According to an abstract presented at the 14th International Congress on Drug Therapy and HIV Infection, enrolment of the trial was halted due to projected inability to recruit the planned 60 participants in a reasonable time period.